Immix Biopharma, Inc. (IMMX)
NCM · Healthcare · Biotechnology
$8.12
+0.93%
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
Market Cap
$673.6M
Shares Outstanding
82.9M
Exchange
NCM
Currency
USD
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (7.7M) | (10.9M) | (10.8M) | (12.5M) |
| Net Income | (7.6M) | (10.7M) | (10.1M) | (11.6M) |
| Diluted EPS | $-0.24 | N/A | $-0.18 | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (8.2M) | (16.1M) | (22.7M) | (30.0M) |
| Net Income | (8.2M) | (15.4M) | (21.6M) | (29.4M) |
| Diluted EPS | $-0.59 | $-0.89 | $-0.76 | N/A |